- Home
- ACTU vs ENX Comparison
ACTU vs ENX Comparison
Compare ACTU & ENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACTU
- ENX
- Stock Information
- Founded
- ACTU 2015
- ENX 2002
- Country
- ACTU United States
- ENX United States
- Employees
- ACTU N/A
- ENX N/A
- Industry
- ACTU
- ENX Finance/Investors Services
- Sector
- ACTU
- ENX Finance
- Exchange
- ACTU NYSE
- ENX Nasdaq
- Market Cap
- ACTU 153.1M
- ENX 175.5M
- IPO Year
- ACTU 2024
- ENX N/A
- Fundamental
- Price
- ACTU $7.53
- ENX $9.43
- Analyst Decision
- ACTU
- ENX
- Analyst Count
- ACTU 0
- ENX 0
- Target Price
- ACTU N/A
- ENX N/A
- AVG Volume (30 Days)
- ACTU 74.0K
- ENX 25.4K
- Earning Date
- ACTU 11-13-2024
- ENX 01-01-0001
- Dividend Yield
- ACTU N/A
- ENX 3.94%
- EPS Growth
- ACTU N/A
- ENX N/A
- EPS
- ACTU N/A
- ENX 0.16
- Revenue
- ACTU N/A
- ENX N/A
- Revenue This Year
- ACTU N/A
- ENX N/A
- Revenue Next Year
- ACTU N/A
- ENX N/A
- P/E Ratio
- ACTU N/A
- ENX $61.00
- Revenue Growth
- ACTU N/A
- ENX N/A
- 52 Week Low
- ACTU $5.51
- ENX $7.84
- 52 Week High
- ACTU $10.16
- ENX $10.07
- Technical
- Relative Strength Index (RSI)
- ACTU N/A
- ENX 29.82
- Support Level
- ACTU N/A
- ENX $9.64
- Resistance Level
- ACTU N/A
- ENX $9.89
- Average True Range (ATR)
- ACTU 0.00
- ENX 0.09
- MACD
- ACTU 0.00
- ENX -0.06
- Stochastic Oscillator
- ACTU 0.00
- ENX 13.37
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
About ENX Eaton Vance New York Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance New York Municipal Bond Fund is principally engaged in managing investment funds and providing investment management and advisory services to high-net-worth individuals and institutions. It is a non-diversified, closed-end investment company. Its objective is to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in specified state.